Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Rebamipide in Korean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were selected after passing a clinical screening procedure that included a physical examination and laboratory tests (blood analysis; hemoglobin, hematocrit, RBC, WBC, platelet, differential counting of WBC, total proteins, albumin, ALT, AST, alkaline phosphatase, total bilirubin, cholesterol, creatinine, blood urea nitrogen, and fasting glucose and urine analysis; specific gravity, color, pH, sugar, albumin, bilirubin, RBC, WBC and cast).~Exclusion Criteria:~* Subjects possibly sensitive to this type of preparation,~* Subjects who had a history of any hepatic illness,~* Subjects who had a history of any renal illness,~* Subjects who had a history of any respiratory illness,~* Subjects who had a history of any endocrine illness,~* Subjects who had a history of any cardiovascular system illness,~* Subjects who had taken alcohol within 4 weeks prior to the study,~* Subjects who had taken other preparations within 4 weeks prior to the study.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Rebamipide, Serum concentration, Tablet (Type: EXPERIMENTAL): The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)

Based on this trial design, predict the completion outcome and termination type (if applicable).